[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filing for Amneal Pharmaceuticals (AMRX) reports a proposed insider sale of 50,000 shares of common stock with an aggregate market value of $453,000. The filing lists 314,079,309 shares outstanding, and the approximate date of sale is 08/12/2025 on Nasdaq. The shares were originally acquired on 07/05/2018 as equity compensation.

The filing also discloses a recent sale of 49,140 shares on 05/16/2025 generating $370,541, and includes the standard insider representation that the seller is not aware of any undisclosed material adverse information. The notice documents compliance with Rule 144 procedures but does not provide additional operational or financial data.

Positive

• None.

Negative

• Proposed insider sale disclosed: 50,000 shares with aggregate market value of $453,000, representing approximately 0.016% of outstanding shares (314,079,309).

Insights

Financial Analyst

TL;DR: Small, routine insider sale; immaterial to company valuation given the very small share percentage and modest proceeds.

The filing shows a proposed sale of 50,000 common shares valued at $453,000 against 314,079,309 shares outstanding, representing roughly 0.016% of the company. That scale suggests the transaction is unlikely to move market valuation or signal a material change in company fundamentals. The seller acquired the shares as equity compensation on 07/05/2018, and a prior sale of 49,140 shares on 05/16/2025 for $370,541 is reported, indicating limited recent insider liquidity events. Impact is routine; monitor only if sale activity accelerates.

Corporate Governance Expert

TL;DR: Filing is procedurally compliant under Rule 144 and contains no governance red flags in itself.

The Form 144 discloses acquisition details, the nature of acquisition as equity compensation, and a representation that no undisclosed material adverse information exists. These elements reflect standard disclosure practice for insider sales. The filing does not identify the filer CIK or additional governance context within the document itself, so assessment is limited to the sale disclosure. Absent further patterns of sales or contrary disclosures, this filing alone does not indicate governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262	50000	453000.00	314079309	08/12/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/05/2018	Equity Compensation	Issuer			50000	07/05/2018	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Nikita Shah 400 Crossing Boulevard Bridgewater NJ 08807	Common	05/16/2025	49140	370541.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Amneal (AMRX) Form 144 disclose?

It discloses a proposed sale of 50,000 common shares valued at $453,000 with an approximate sale date of 08/12/2025 on Nasdaq.

When and how were the shares being sold acquired?

The 50,000 shares were acquired on 07/05/2018 as equity compensation.

Were there recent sales by the same person in the past three months?

Yes. The filing reports a sale of 49,140 shares on 05/16/2025 for gross proceeds of $370,541 by Nikita Shah.

How large is the proposed sale relative to Amneal's outstanding shares?

The proposed 50,000-share sale represents approximately 0.016% of the 314,079,309 shares reported as outstanding.

Does the filing indicate any undisclosed material adverse information?

The filer represents by signature that they do not know of any material adverse information not publicly disclosed.